Make Big Pharma An Offer They Can’t Refuse

Modern medicine is facing the convergence of 2 major problems: the rise of antibiotic resistance and the fall of efforts to find badly needed replacements, write Allan Coukell and Helen W. Boucher.

In 2018 alone, 3 Big Pharma firms halted antibiotics R&D; others have slashed their efforts.

“We need to fundamentally change how the market for new antibiotics works”—with economic incentives that would reward companies that develop new antibiotics with a higher return on their product, the pair writes 

With drug prices already sky-high, this recommendation is not to be taken lightly, they note—but this unique class of drugs requires a special solution.

The Hill (opinion)

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top